Drug Profile
KP 0832
Alternative Names: KP-0832; Macrocyclic peptide therapeutic - Biohaven Labs/PeptiDreamLatest Information Update: 29 Jan 2021
Price :
$50
*
At a glance
- Originator Kleo Pharmaceuticals; PeptiDream
- Developer Biohaven Labs; PeptiDream
- Class Antineoplastics; Immunotherapies; Peptides; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 07 Jan 2021 Kleo Pharmaceuticals was acquired and merged into Biohaven Pharmaceutical Holding Company to form Biohaven Labs
- 24 Jun 2020 Preclinical trials in Prostate cancer in Japan, USA (unspecified route), prior to June 2020 (Kleo Pharmaceuticals pipeline, June 2020)
- 07 Nov 2018 Kleo Pharmaceuticals plans a clinical trial for KP 0832 in Cancer, in 2020